Pharmacology & Therapeutics

Article	Citations
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	430
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	315
Editorial Board	309
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy	269
Non-canonical G protein signaling	255
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	240
Potential neonatal toxicity of new psychoactive substances	220
Collateral lethality: A unique type of synthetic lethality in cancers	209
Unfolded protein responses: Dynamic machinery in wound healing	209
Inflammation, lipids, and pain in vulvar disease	179
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications	175
In cancer, all roads lead to NADPH	174
Exploiting the obesity-associated immune microenvironment for cancer therapeutics	171
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	171
Matrikines in the skin: Origin, effects, and therapeutic potential	154
Adenosine receptor signalling as a driver of pulmonary fibrosis	151
Retinoid dynamics in vision: from visual cycle biology to retina disease treatments	134
Endothelial dysfunction as a complication of anti-cancer therapy	133
The role of macrophages in asthma-related fibrosis and remodelling	130
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	128
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	125
Boron in cancer therapeutics: An overview	124
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	124
Sleep apnea and pulmonary hypertension: A riddle waiting to be solved	120
Dysregulation of metabolic pathways in pulmonary fibrosis	114

Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	108
TAAR1 as an emerging target for the treatment of psychiatric disorders	107
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?	103
Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics	100
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	98
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	98
TLR4 biased small molecule modulators	98
Management of drug-resistant hypertension as a heterogeneous disorder	97
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	95
Contribution of non-selective membrane channels and receptors in epilepsy	94
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	92
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	90
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	88
Cell-based therapies for vascular regeneration: Past, present and future	87
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	86
Bispecific antibodies for the treatment of neuroblastoma	86
Corrigendum to “The role of CD71+ erythroid cells in the regulation of the immune response” [Pharmacology & Therapeutics 228 (2021) 107927]	85
Editorial Board	84
Pharmacological treatment of cardiogenic shock – A state of the art review	82
Review: Sex-related differences in the treatment of cardiac arrhythmia	82
Natural products that alleviate depression: The putative role of autophagy	82
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents	80
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance	80
Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression	77
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	75
Wnt signaling: A prospective therapeutic target for chronic pain	74
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease	70
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	70
G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs)	69
Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms	69
Targeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy	69
PGRMC1: An enigmatic heme-binding protein	69
Stabilizing the neural barrier – A novel approach in pain therapy	68
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy	67
HDL-based therapeutics: A promising frontier in combating viral and bacterial infections	67
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases	67
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response	67
DNA methylation in cell plasticity and malignant transformation in liver diseases	66
CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer	65
The role of microglia heterogeneity in synaptic plasticity and brain disorders: Will sequencing shed light on the discovery of new therapeutic targets?	65
Advances in pathogenesis and therapeutic strategies for osteoporosis	64
Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines	62
Optimizing drug therapies in cardiac amyloidosis	61
Editorial Board	61
Neuromuscular and cardiac organoids and assembloids: Advanced platforms for drug testing	60
The role of drug-metabolizing enzymes in synthetic lethality of cancer	59
Drug repurposing for COVID-19: Approaches, challenges and promising candidates	57
Regulation of feeding and therapeutic application of bioactive peptides	57
17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease	57
Extracellular vesicles in cardiovascular disease: Biological functions and therapeutic implications	57

Therapeutic targeting of DNA methylation alterations in cancer	56
The therapeutic potential of Nrf2 inducers in chronic pain: Evidence from preclinical studies	56
In vitro functional assays as a tool to study new synthetic opioids at the μ-opioid receptor: Potential, pitfalls and progress	56
Emerging roles of RNA ac4C modification and NAT10 in mammalian development and human diseases	55
Recent advances in riboflavin transporter RFVT and its genetic disease	55
Chemical diversity, traditional uses, and bioactivities of Rosa roxburghii Tratt: A comprehensive review	55
Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response	55
MAS-related G protein-coupled receptors X (MRGPRX): Orphan GPCRs with potential as targets for future drugs	55
Endothelial shear stress signal transduction and atherogenesis: From mechanisms to therapeutics	54
Myeloperoxidase: Growing importance in cancer pathogenesis and potential drug target	54
Editorial Board	53
Bridging the gap: The endocannabinoid system as a functional fulcrum for benzodiazepines in a novel frontier of anxiety pharmacotherapy	53
MicroRNAs in drug addiction: Current status and future perspectives	52
Editorial Board	52
The emerging science of Glioception: Contribution of glia in sensing, transduction, circuit integration of interoception	50
Consideration of albumin-mediated hepatic uptake for highly protein-bound anionic drugs: Bridging the gap of hepatic uptake clearance between in vitro and in vivo	50
Pharmacological potential of cyclic nucleotide signaling in immunity	49
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation	49
Update on treatment of abdominal pain in irritable bowel syndrome: A narrative review	48
Organic anion transporters in remote sensing and organ crosstalk	48
Lactate acidosis and simultaneous recruitment of TGF-β leads to alter plasticity of hypoxic cancer cells in tumor microenvironment	48
Emerging methods for and novel insights gained by absolute quantification of mitochondrial DNA copy number and its clinical applications	48
Pathological changes in GPCR signal organisation: Opportunities for targeted therapies for triple negative breast cancer	48
Musculoskeletal crosstalk in chronic obstructive pulmonary disease and comorbidities: Emerging roles and therapeutic potentials	48
The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications	48
Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery	47
CDNF and ER stress: Pharmacology and therapeutic possibilities	47
Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders	47
Integrins in cancer: Emerging mechanisms and therapeutic opportunities	47
Pharmacological interventions for intraplaque neovascularization in atherosclerosis	46
G protein-coupled estrogen receptor biased signaling in health and disease	46
Immunotherapy for hepatocellular carcinoma: Recent advances and future targets	46
Editorial Board	46
The (neuro)inflammatory system in anxiety disorders and PTSD: Potential treatment targets	45
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions	45
The tissue-specific transcriptional landscape underlines the involvement of endothelial cells in health and disease	45
Modulation of hyaluronan signaling as a therapeutic target in human disease	45
Biased agonism in drug discovery: Is there a future for biased 5-HT1A receptor agonists in the treatment of neuropsychiatric diseases?	45
Neurobiological mechanisms of botulinum neurotoxin-induced analgesia for neuropathic pain	45
Exploring the landscape of post-translational modification in drug discovery	44
Resolving inflammation by TAM receptor activation	44
The role and participation of immune cells in the endometrial tumor microenvironment	44
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination	44
Editorial Board	43
The role of osteoprotegerin (OPG) in fibrosis: its potential as a biomarker and/or biological target for the treatment of fibrotic diseases	43
Understanding the molecular bridges between the drugs and immune cell	43
Molecular mechanisms of ferroptosis and their involvement in brain diseases	43
Attributes novel drug candidate: Constitutive GPCR signal bias mediated by purinergic receptors	43
Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects	42
Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?	41
Phosphorylation of nuclear receptors: Novelty and therapeutic implications	41
Potential targeting of the tumor microenvironment to improve cancer virotherapy	41
Platelet lipid metabolism in vascular thrombo-inflammation	41
Experimental considerations for the assessment of in vivo and in vitro opioid pharmacology	40
Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities	39
Editorial Board	38
From bench to clinic: Emerging therapies for corneal scarring	38
Post-COVID pulmonary sequelae: Mechanisms and potential targets to reduce persistent fibrosis	38
Annexin A1 in neurological disorders: Neuroprotection and glial modulation	38
Prolactin and pain of endometriosis	38
Signaling pathways in brain ischemia: Mechanisms and therapeutic implications	37
Targeting the Semaphorin3E-plexinD1 complex in allergic asthma	37
Therapeutic antibodies – natural and pathological barriers and strategies to overcome them	37
Nanotechnology and nano-sized tools: Newer approaches to circumvent oncolytic adenovirus limitations	37
Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities	36
The essential role of docosahexaenoic acid and its derivatives for retinal integrity	36
Roles of NLRC4 inflammasome in neurological disorders: Mechanisms, implications, and therapeutic potential	36
Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets	36
Modulating glucocorticoid receptor actions in physiology and pathology: Insights from coregulators	35
Plant-derived nanovesicles and therapeutic application	35
The antidepressant actions of ketamine and its enantiomers	35
Early life adversities, psychopathologies and novel pharmacological strategies	35
Resolution of inflammation: An organizing principle in biology and medicine	35
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy	35
Editorial Board	34
Editorial Board	34
Gene and stem cell therapy for inherited cardiac arrhythmias	34
Post-translational modifications of histone and non-histone proteins in epigenetic regulation and translational applications in alcohol-associated liver disease: Challenges and research opportunities	33
Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease	33
GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?	33

Icosapent ethyl in cardiovascular prevention: Resolution of inflammation through the eicosapentaenoic acid - resolvin E1 - ChemR23 axis	33
Anti-cancer activity of sustained release capsaicin formulations	32
Retina-directed gene therapy: Achievements and remaining challenges	32
Treatment of overdose in the synthetic opioid era	32
Biased signaling in drug discovery and precision medicine	32
Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics	32
Chloride channels in the lung: Challenges and perspectives for viral infections, pulmonary arterial hypertension, and cystic fibrosis	31
Spotlight on plasticity-related genes: Current insights in health and disease	31
Gut dysbiosis, defective autophagy and altered immune responses in neurodegenerative diseases: Tales of a vicious cycle	31
Current state and novel outlook on prevention and treatment of rising antibiotic resistance in urinary tract infections	31
Bile acids and neurological disease	31
Multitasking bamboo leaf-derived compounds in prevention of infectious, inflammatory, atherosclerotic, metabolic, and neuropsychiatric diseases	31
Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics	31
Endotheliopathy in the metabolic syndrome: Mechanisms and clinical implications	31
Editorial Board	31